Skip to main content

Table 1 Therapeutic efficacy of 18F-metabolic TRT or EBRT, alone, or combined with i.t. 5FU in the HCT116 human colorectal cancer xenografts

From: Intratumoral 18F-FLT infusion in metabolic targeted radiotherapy

  1. aControl animals received 0.9% NaCl solution
  2. bThe single i.t. infusion of 2.5 mg 5FU was administered 4 h prior i.t. infusion of 18F-FLT or 18F-FDG, or of a single 15 Gy dose EBRT
  3. cFive times tumor growth delay (5Td) was determined as the time required for the tumor volume to increase fivefold over the initial volume at the start of treatment
  4. dTumor growth delay (TGD) = 5Td of the treated group – 5Td of the non-treated group
  5. eThe enhancement factor (EF) = 5Td of the treated group/5Td of the non-treated group
  6. fGrowth of contralateral tumors after i.t. 18F-FLT 10 MBq into the primary tumor
  7. g5TD p value of each treatment conditions in comparison with the control group, One-way ANOVA, F(10,27) = 130.2, p < 0.0001, Dunnett’s test and comparison of (i.t. 5FU + 15 Gy EBRT) with (i.t. 5FU + i.t. 18F-FLT 15 MBq) and (i.t. 5FU + i.t. 18F-FDG 15 MBq) Tukey’s multiple comparison test. ns: p > 0.05; *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001 ****p ≤ 0.0001. Two to four animals were included in each group